Showing 1981-1990 of 2192 results for "".
- Byrostatin Improves Cognition in Advanced Alzheimer Diseasehttps://practicalneurology.com/news/byrostatin-improves-cognition-in-advanced-alzheimer-disease/2469812/An article published in the Journal of Alzheimer Disease provides evidence from 2 placebo-controlled trials that bryostatin (DB11752; Synaptogenix Inc., New York, NY) improved cognition from baseline in individuals with advanced Alzheimer disea
- A New Phase 2 Trial of Tominersen for Early Huntington Disease Designedhttps://practicalneurology.com/news/a-new-phase-2-trial-of-tominersen-for-early-huntington-disease-designed/2469801/A new phase 2 trial is planned to evaluate tominersen (IONIS-HTTRx; Ionis Pharmaceuticals, Carlsbad, CA) to treat early-stage Huntington disease (HD). Although the phase 3 GENERATION HD1 trial of tominersen for HD was halted, post hoc analyses suggest tominersen may benefit younger adults with lo
- First Participant Enrolls in Clinical Trial of Vidofludimus Calcium for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/first-participant-enrolls-in-clinical-trial-of-vidofludimus-calcium-for-relapsing-multiple-sclerosis/2469799/The twin phase 3 clinical trials ENSURE-1 clinical trial (NCT05134441) of vidofludimus calcium (IMU-838; Immunic Therapeutics, New York, NY) enrolled the first participant for potential trea
- First Participant Dosed of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/first-participant-dosed-of-novel-chimeric-cell-therapy-for-duchenne-muscular-dystrophy/2469789/The first patient has been treated in a phase 1 clinical study of dystrophin-expressing chimeric cells (DEC)(DT-DEC01; Dystrogen Therapeutics, Miami, FL) for the treatment of Duchenne muscular dystrophy (DMD). The first participant, age 6 years, received an infusion of DEC, tolerated th
- Combination Extended Release Pramipexole/Rasagiline Effective for Parkinson Diseasehttps://practicalneurology.com/news/combination-extended-release-pramipexolerasagiline-effective-for-parkinson-disease/2469780/In a phase 3 study (NCT03329508), a combination therapy of pramipexole/rasagiline (P2B001; Pharma Two B, Rehovot, Israel) was superior compared with either pramipexole or rasagiline individually f
- Zavegepant Treatment Results in Rapid Pain Relief of Migraine Within 15 Minuteshttps://practicalneurology.com/news/zavegepant-demonstrates-rapid-pain-relief-of-migraine-within-15-minutes/2469774/In clinical trials, intranasal zavegepant (Biohaven, New Haven, CT) demonstrated statistically significant superiority vs placebo on a total of 15 consecutive outcome measure in the acute treatment of migraine. Zavegepant treatment resulted in pain relief at the earliest measured time p
- Diagnostic Delay for Focal Epilepsy Is Significantly Longer in Children and Adolescentshttps://practicalneurology.com/news/diagnostic-delay-for-focal-epilepsy-is-significantly-longer-in-children-and-adolescents/2469768/Retrospective analysis of data from the Human Epilepsy Project, showed time to diagnosis of epilepsy in people with focal seizure onset before vs after age 18 years was a median 340 vs 207 days (P=.012). For those who had only nonmotor focal seizures, the mean time to diagnosis was 1,019
- Evidence of Utility of Gene Testing for Children with Unexplained Epilepsy Continues to Growhttps://practicalneurology.com/news/evidence-of-utility-of-gene-testing-for-children-with-unexplained-epilepsy-continues-to-grow/2469767/Analysis of 152 children with unexplained epilepsy treated at a single institution had care that was substantially affected by genetic evaluation, suggesting any child with unexplained epilepsy should have such an evaluation. Of those tested, 72% had changes in medical care in at
- First Participant Enrolled in Phase 3 Study of Vidofludimus Calcium for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/first-participant-enrolled-in-phase-3-study-of-vidofludimus-calcium-for-relapsing-multiple-sclerosis/2469761/The first participant has enrolled in the phase 3 ENSURE-1 clinical trial (NCT05134441) of vidofludimus calcium (IMU-838; Immunic Therapeutics, New York, NY) for potential treatment of relapsing m
- FDA Accepts Investigational New Drug Application and Grants Fast Track Designation of Trehalose for Spinocerebellar Ataxia Treatmenthttps://practicalneurology.com/news/fda-accepts-investigational-new-drug-application-and-grants-fast-track-designation-of-trehalose-for-spinocerebellar-ataxia-treatment/2469747/The Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application to trehalose (SLS-005; Seelos Therapeutics, New York, NY) for spinocerebellar ataxia (SCA) treatment. The FDA has granted the program Fast Track designation for SCA, and trehalose has previously rec